Short Interest in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Decreases By 71.7%

Posted by Trevor Kearing on Dec 25th, 2025

Fidelity Disruptive Medicine ETF (NASDAQ:FMED – Get Free Report) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totaling 2,524 shares, a decline of 71.7% from the November 30th total of 8,926 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 7,740 shares, the short-interest ratio is currently 0.3 days. Based on an average trading volume of 7,740 shares, the short-interest ratio is currently 0.3 days. Currently, 0.1% of the shares of the stock are sold short.

Fidelity Disruptive Medicine ETF Stock Performance

Shares of FMED opened at $27.61 on Thursday. The stock has a 50 day moving average price of $27.22 and a 200 day moving average price of $25.30. Fidelity Disruptive Medicine ETF has a one year low of $20.69 and a one year high of $29.07. The stock has a market capitalization of $60.74 million, a price-to-earnings ratio of 41.33 and a beta of 1.00.

Institutional Investors Weigh In On Fidelity Disruptive Medicine ETF

An institutional investor recently raised its position in Fidelity Disruptive Medicine ETF stock. Wealth Enhancement Advisory Services LLC grew its stake in Fidelity Disruptive Medicine ETF (NASDAQ:FMED – Free Report) by 12.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 688,750 shares of the company’s stock after acquiring an additional 76,538 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 31.31% of Fidelity Disruptive Medicine ETF worth $16,544,000 as of its most recent SEC filing.

About Fidelity Disruptive Medicine ETF

(Get Free Report)

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.